Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1 3Phase 1/2 2Phase 3 1Phase 2/3 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 12Other hematologic neoplasm 10Thoracic 9Gastrointestinal 9CNS 8Myeloid 6Head & Neck 6Endocrine 5Sarcoma 4Breast 4Genitourinary 3Tumor-Agnostic 2Plasma cell 2Other solid neoplasm 2NET 2Gynecologic 1

Conditions

KRAS p.G12C Mutant Advanced Solid Tumors 1Advanced or Metastatic Solid Tumors 1

Interventions

sotorasib 1cobimetinib 1Nivolumab 1Midazolam 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Has announcements × Other solid neoplasm × Clear all
NCT03600883 2026-03-16

A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

Amgen

Phase 1/2 Active not recruiting
713 enrolled 1 FDA
Other solid neoplasm

KRAS p.G12C Mutant Advanced Solid Tumors

NCT01928394 2024-12-27

A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors

Bristol-Myers Squibb

Phase 1/2 Completed
1,163 enrolled 33 charts 1 FDA
Other solid neoplasm

Advanced or Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡